Local chemotherapy of malignant glioma: From syringe injections to nanotechnology;Chimiothérapie locale dans les gliomes malins : de l'injection à la seringue aux nanotechnologies

Revue Neurologique

Volumn 164, Issue 6-7, 2008, Pages 547-553

  Petit, S ^a,b   Garcion, E ^a   Benoit, J P ^a   Menei, P ^a,c  

^a INSERM   (France)

^b CENTRE PAUL PAPIN   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Lipid nanoparticles; Local therapy; Malignant gliomas; Microscopic polymeric systems

Indexed keywords

BLEOMYCIN; CAMPTOTHECIN; CARMUSTINE; CYCLOPHOSPHAMIDE; METHOTREXATE; NIMUSTINE; PACLITAXEL; TEMOZOLOMIDE; TIRAPAZAMINE;

CANCER CHEMOTHERAPY; CANCER RESEARCH; GLIOBLASTOMA; NANOTECHNOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; GLIOMA; HUMANS; INJECTIONS; MICROINJECTIONS; NANOPARTICLES; NANOTECHNOLOGY; SYRINGES;

EID: 45949101642     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2008.03.015     Document Type: Review

References (77)

1. Bankiewicz K.S., Eberling J.L., Kohutnicka M., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164 (2000) 2-14
2. Batrakova E., Lee S., Li S., Venne A., Alakhov V., and Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16 (1999) 1373-1379
3. Batrakova E.V., Li S., Alakhov V.Y., Elmquist W.F., Miller D.W., and Kabanov A.V. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm. Res. 20 (2003) 1581-1590
4. Batrakova E.V., Zhang Y., Li Y., et al. Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood-brain barrier. Pharm. Res. 21 (2004) 1993-2000
5. Bobo R.H., Laske D.W., Akbasak A., et al. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U S A. 91 (1994) 2076-2080
6. Boisdron-Celle M., and Benoit J.P. Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J. Pharm. Pharmacol. 47 (1995) 108-111
7. Brem H., Mahaley M.S., Vick N.A., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74 (1991) 441-446
8. Brem H., Tamargo R.J., Olivi A., et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J. Neurosurg. 80 (1994) 283-290
9. Brem H., Piantadosi S., Burger P.C., et al. Polymer-brain tumor group: intraoperative controlled delivery of chemotherapy by biodegradable polymers: safety and effectiveness for recurrent gliomas evaluated by a prospective multi-institutional placebo-controlled clinical trial. Lancet 345 (1995) 1008-1012
10. Brem H., Ewend M.G., Piantadosi S., et al. The safety of intersitital chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J. Neurooncol. 26 (1995) 111-123
11. Brigger I., Morizet J., Laudani L., et al. Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Control Release 100 (2004) 29-40
12. Chen M.Y., Lonser R.R., Morrison P.F., et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg. 90 (1999) 315-320
13. Couvreur P., Barratt G., Fattal E., Legrand P., and Vauthier C. Nanocapsule technology: a review. Crit. Rev. Ther. Drug Carrier. Syst. 19 (2002) 99-134
14. Cowens J.W., Creaven P.J., Greco W.R., et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 53 (1993) 2796-2802
15. Damascelli B., Marchiano A., Frigerio L.F., et al. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma. Cancer 68 (1991) 995-998
16. Donelli M.G., Zucchetti M., and D'Incalci M. Do anticancer agents reach the tumor target in the human brain?. Cancer Chemother. Pharmacol. 30 (1992) 251-260
17. Folkman J., and Long D.M. The use of silicone rubber as a carrier for prolonged drug therapy. J. Surg. Res. 4 (1964) 139-142
18. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
19. Garcion E., Lamprecht A., Heurtault B., et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5 (2006) 1710-1722
20. Geze A., Venier-Julienne M.C., Saulnier P., et al. Modulated release of IudR from poly-(D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers. J. Control Release 58 (1999) 311-322
21. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
22. Grossman S.A., Rienhard C., Colvin O.M., et al. The intracerebral delivery of BCNU by surgically implanted biodegradable polymers. J. Neurosurg. 76 (1992) 640-647
23. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19 (2002) 875-880
24. Hu Y.P., Jarillon S., Dubernet C., Couvreur P., and Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother. Pharmacol. 37 (1996) 556-560
25. Judy K., Olivi A., Buahin K.G., et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymer against rat gliomas. J. Neurosurg. 82 (1995) 481-486
26. Kaiser M.G., Parsa A.T., Fine R.L., et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47 (2000) 1391-1398
27. Koennings S., Garcion E., Faisant N., Menei P., Benoit J.P., and Goepferich A. In vitro investigation of lipid implants as a controlled release system for interleukin-18. Int. J. Pharm. 314 (2006) 145-152
28. Krauze M.T., McKnight T.R., Yamashita Y., et al. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain. Res. Brain. Res. Protoc. 16 (2005) 20-26
29. Kubo O., Tajika Y., Muragaki Y., et al. Local chemotherapy with slowly-releasing anticancer drug-polymers for malignant brain tumors. J. Control Rel. 32 (1994) 1-8
30. Lagarce F., Garcion E., Faisant N., Thomas O., Kanaujia P., Menei P., and Benoit J.P. Development and characterization of interleukin-18-loaded biodegradable microspheres. Int. J. Pharm. 314 (2006) 179-188
31. Langer R. Polymer implants for drug delivery in the brain. J. Contr. Rel. 16 (1991) 53-60
32. Levy R.M., Major E., Ali M.J., et al. Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J. Neurovirol. 7 (2001) 382-385
33. Liang B.C., Thornon Jr. A.F., Sandler H.M., et al. Malignant astrocytomas: focal recurrence after focal external beam radiation therapy. J. Neurosurg. 75 (1991) 559-563
34. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J. Neurosurg. 100 (2004) 472-479
35. Lieberman D.M., Laske D.W., Morrison P.F., et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82 (1995) 1021-1029
36. Lonser R.R., Walbridge S., Murray G.J., et al. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann. Neurol. 57 (2005) 542-548
37. Lu D.R., Mehta S.C., and Chen W. Selective boron drug delivery to brain tumors for boron neutron capture therapy. Adv. Drug Deliv. Rev. 26 (1997) 231-247
38. Menei P., Daniel V., Montero-Menei C., et al. Biodegradation and brain tissue reaction to poly-(D-L lactide-co-glycolide) microspheres. Biomaterials 14 (1993) 470-478
39. Menei P., Croue A., Daniel V., et al. Fate and biocompatibility of three types of microspheres implanted into the brain. J. Biomed. Mater. Res. 28 (1994) 1079-1085
40. Menei P., Benoit J.P., Boisdron-Celle, et al. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 34 (1994) 1058-1064
41. Menei P., Boisdron-Celle M., Croue A., et al. Effect of stereotactic implantation of biodegradable 5-Fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 39 (1996) 117-124
42. Menei P., Venier M.C., Gamelin E., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer 86 (1999) 325-333
43. Menei P., Jadaud E., Faisant N., et al. Stereotaxic implantation of 5-FU-releasing microspheres in malignant glioma. Cancer 100 (2004) 405-410
44. Menei P., Capelle L., Guyotat J., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56 (2005) 242-248
45. Moffat B.A., Reddy G.R., McConville P., et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol. Imaging 2 (2003) 324-332
46. Montet X., Montet-Abou K., Reynolds F., Weissleder R., and Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 8 (2006) 214-222
47. Muller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113 (2004) 151-170
48. Nierenberg D., Harbaugh R., Maurer L.H., et al. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery 28 (1991) 752-761
49. Oda Y., Ochida Y., Murata T., et al. Treatment of brain tumors with anticancer pellet: experimental and clinical study. No Shinkei Geka 10 (1982) 375-381
50. Olivi A., Gilbert M., Duncan K.L., Corden B., Lanartz D., and Brem H. Direct delivery of platinium-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother. Pharmacol. 31 (1993) 449-454
51. Plotkin M., Gneveckow U., Meier-Hauff K., et al. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int. J. Hyperthermia. 22 (2006) 319-325
52. Rahman A., Treat J., Roh J.K., Potkul L.A., Alvord W.G., Forst D., and Woolley P.V. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol. 8 (1990) 1093-1100
53. Ramaswamy M., Zhang X., Burt H.M., and Wasan K.M. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 86 (1997) 460-464
54. Saito R., Krauze M.T., Noble C.O., et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncol 8 (2006) 205-214
55. Sells R.A., Owen R.R., New R.R., and Gilmore I.T. Reduction in toxicity of doxorubicin by liposomal entrapment. Lancet 2 (1987) 624-625
56. Sibergeld D.L., and Chicoine M.R. Isolation and characterization of human glioma cells from histologically normal brain. J. Neurosurgery 86 (1997) 525-531
57. Sipos E.P., and Brem H. Local-antiangiogenic brain tumor therapies. J. Neurooncol. 50 (2000) 181-188
58. Soma C.E., Dubernet C., Bentolila D., Benita S., and Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21 (2000) 1-7
59. Steiniger S.C., Kreuter J., Khalansky A.S., et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
60. Storm G., ten Kate M.T., Working P.K., and Bakker-Woudenberg I.A. Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin. Cancer Res. 4 (1998) 111-115
61. Tamargo R.J., Epstein J.I., Reinhard C.S., et al. Brain biocompatibility of a biodegradable controlled release polymer in rats. J. Biomed. Mater. Res. 23 (1989) 253-266
62. Tamargo R.J., Myseros J.S., Epstein J.I., Yang M.B., Chesin M., and Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 53 (1993) 329-333
63. Trehin R., Figueiredo J.L., Pittet M.J., Weissleder R., Josephson L., and Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 8 (2006) 302-311
64. Valtonen S., Timonen U., Toivanen P., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41 (1997) 44-49
65. Vauthier C., Dubernet C., Chauvierre C., Brigger I., and Couvreur P. Drug delivery to resistant tumors: the potential of poly-(alkyl cyanoacrylate) nanoparticles. J. Control Release 93 (2003) 151-160
66. Veiseh O., Sun C., Gunn J., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 5 (2005) 1003-1008
67. Veziers J., Lesourd M., Jollivet C., et al. Brain biocompatibility of drug releasing biodegradable microspheres analyzed by scanning and electronic microscopy. J. Neurosurg. 95 3 (2001) 489-494
68. Wallner K.E., Galicich J.H., Krol G., et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 16 (1989) 1405-1409
69. ® delivered from a biodegradable polymer implanted against experimental malignant glioma. Cancer Res. 54 (1994) 2207-2212
70. Walter K.A., Tamargo R.J., Olivi A., et al. Intratumoral chemotherapy. Neurosurgery 37 (1995) 1129-1145
71. Weingart J.D., Thompson R.C., Tyler B., et al. Local delivery of the Topoisomerase I inhibitor camptothecin prolongs survival in the rat intracranial 9L gliosarcoma model. Int. J. Cancer 62 (1995) 605-609
72. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5 (2003) 79-88
73. Wiranowska M., Ransihoff J., Weingart J.D., et al. Interferon-containing controlled release polmymers for localized cerebral immunotherapy. J. Interferon. Cytokine Res. 18 (1998) 377-385
74. Wu M.P., Tamada J.A., Brem H., et al. In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy. J. Biomed. Mater.Res. 28 (1994) 387-395
75. Yamashima T., Yamashita J., and Shoin K. Neurotoxicity of local administration of two nitrosoureas in malignant gliomas. Neurosurgery 26 (1990) 794-800
76. Yuan X., Tabassi K., and Williams J.A. Implantable polymers for tirapazamine treatments of experimental intrarcanial malignant glioma. Radiat. Oncol. Investig. 7 (1999) 218-230
77. Yuan X., Dillehay L.E., Williams J.R., et al. IudR polymers for combined continupous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas. Int. J. Cancer 96 (2001) 118-125